NYMOX PHARMACEUTICAL CORPORATION (NYMXF) Free cash flow 2016–2024
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$2.6MFY2024 · since FY2016: -$4.5M → -$2.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$2.6M | +35.9% |
| FY2023 | -$4.1M | +22.0% |
| FY2022 | -$5.2M | +47.0% |
| FY2021 | -$9.8M | +2.2% |
| FY2020 | -$10.1M | -35.3% |
| FY2019 | -$7.4M | +5.2% |
| FY2018 | -$7.8M | — |
| FY2016 | -$4.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NYMXF financial trends
NYMXF RevenueNYMXF Net incomeNYMXF Net marginNYMXF Gross profitNYMXF Gross marginNYMXF Operating incomeNYMXF Operating marginNYMXF Operating cash flowNYMXF Capital expendituresNYMXF Return on equityNYMXF Stock buybacksNYMXF Dividends paidNYMXF Total assetsNYMXF Total liabilitiesNYMXF Shareholders’ equityNYMXF overview →